{"id":390654,"date":"2018-06-08T00:00:00","date_gmt":"2018-06-08T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0011-2018-biopharma-malignant-melanoma-treatment-sequencing-eu5-2018\/"},"modified":"2026-05-01T11:40:38","modified_gmt":"2026-05-01T11:40:38","slug":"trsqon0011-2018-biopharma-malignant-melanoma-treatment-sequencing-eu5-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/trsqon0011-2018-biopharma-malignant-melanoma-treatment-sequencing-eu5-2018\/","title":{"rendered":"Malignant Melanoma | Treatment Sequencing | EU5 | 2018"},"content":{"rendered":"<p>Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians and DRG oncology experts\u2019 assumptions.<\/p>\n<p><strong>Key Benefits:<\/strong><\/p>\n<ul>\n<li><strong>Pinpoint<\/strong> current drug positioning and uptake in one snapshot to facilitate forecasting.<\/li>\n<li><strong>Drill down<\/strong> into physicians\u2019 treatment sequences and understand who to position against or how to defend share.<\/li>\n<li><strong>Identify<\/strong> untapped treatment scenarios and key competitors to aid trial design.<\/li>\n<li><strong>Evaluate<\/strong> unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources and execute commercialization messages.<\/li>\n<li><strong>Discover<\/strong> untapped populations to expand product share and drive strategic decisions.<\/li>\n<\/ul>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>Where is my product positioned versus that of\u00a0competitors\u00a0in the treatment journey?<\/li>\n<li>What are physicians\u2019 most frequent treatment sequences; who is benefiting, and how can I defend my asset\u2019s share and position?<\/li>\n<li>What are the market-relevant treatment scenarios according to oncology experts?<\/li>\n<li>How can I optimize trial design and ensure a competitive edge for my pipeline asset?<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-390654","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390654\/revisions"}],"predecessor-version":[{"id":393778,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390654\/revisions\/393778"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}